AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02641431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mapping
Description: A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
Study NCT03896321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: effect of dual antiplatelet in management of coronary artery ectasia
Study NCT03896321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: effect of oral anticoagulants in management of coronary artery ectasia
Study NCT02660489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Description: Inoculation with rhinovirus serotype 16
Study NCT01012258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab + concomitant boost radiotherapy
Description: Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval
Study NCT02952599 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study NCT03600740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Programming
Description: DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
Study NCT01450865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flupirtine
Description: Potassium channel opener (SNEPCO)
Study NCT02890602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
Study NCT04412616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.
Study NCT01854970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
Study NCT02445872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
Study NCT02029118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)
Description: Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Study NCT03955341 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diode laser disinfection
Description: After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
Study NCT02029118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)
Description: Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Study NCT02029118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint
Description: select acupoint according to traditional Chinese medicine
Study NCT02029118 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: acupoint
Description: select acupoint according to traditional Chinese medicine
Study NCT02029118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment
Study NCT02029118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment
Study NCT02029118 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment
Study NCT00567008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 1.0 mg BID for 8 weeks
Study NCT00567008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BID for 8 weeks
Study NCT02445872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Study NCT02445872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Study NCT02445872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03955341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chemical disinfection using 2% Chlorhexidine
Description: After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
Study NCT02660489 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rhinovirus
Description: Inoculation with rhinovirus serotype 16
Study NCT02841332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-MISO
Description: The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic.
Study NCT02841332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral magnetic resonance imagery
Description: During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence
Study NCT02841332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
Study NCT02841332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment
Study NCT03028077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GS-3K8
Description: GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
Study NCT03028077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GINst15
Description: GINst15 (hydrolyzed ginseng extract) 1 g/day
Study NCT03028077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 g/day
Study NCT00103389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: PI-88+docetaxel
Study NCT00103389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel only
Study NCT00103389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel only
Study NCT02445872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT01933490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high carbohydrate test meal
Study NCT01933490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high carbohydrate test meal
Study NCT01933490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin
Study NCT01933490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin
Study NCT01933490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Study NCT01933490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Study NCT01586468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WF10
Description: 0.5 mg/kg B.W.
Study NCT01586468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl Solution
Description: NaCl Solution
Study NCT03620669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg q4W until progression or unacceptable toxicity
Study NCT03361709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
Study NCT03361709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solutions, Intraocular
Description: Only saline will be injected intracamerally at conclusion of Phacoemulsification
Study NCT04144309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture (EA) and Auricular Acupressure (AA)
Description: EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments.
Study NCT04144309 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)
Description: SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure.
Study NCT04538716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transconjunctival lower blepharoplasty
Description: transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
Study NCT01985776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: Functional stabilisation exercise for the trunk.
Study NCT01985776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and e-stim
Description: Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
Study NCT03744494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral simple orchidectomy (BSO)
Study NCT03744494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Subcapsular Orchidectomy
Study NCT03744494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Epididymal-sparing Orchidectomy
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, IM at age 9 and 12 months
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella-varicella vaccine
Description: 0.5 mL, intramuscular at 12 months of age
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles-mumps-rubella-varicella vaccine
Description: 0.5 mL, intramuscular at 12 months of age
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine paediatric vaccine - Pneumococcal conjugate (PCV)
Description: 0.5 mL, Intramuscular at age 12 months
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Routine paediatric vaccine - Pneumococcal conjugate (PCV)
Description: 0.5 mL, Intramuscular at age 12 months
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine paediatric vaccine - Hepatitis A
Description: 0.5 mL, Intramuscular at age 12 months
Study NCT00483574 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Routine paediatric vaccine - Hepatitis A
Description: 0.5 mL, Intramuscular at age 12 months
Study NCT01516060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 400mg qd; 2 x 200mg
Study NCT01516060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg qd; 3 x 200mg qd
Study NCT01761461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1, oxaliplatin
Study NCT01761461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TS-1, oxaliplatin
Study NCT00707252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
Study NCT00707252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: All patients will also receive Erlotinib 150mg po/day from Day 1.
Study NCT04310241 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patching therapy, Glasses
Description: Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
Study NCT00457795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine 0.1% (Alphagan® P)
Description: Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
Study NCT01001195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.1%
Description: One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study NCT01001195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.075%
Description: One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study NCT01001195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.05%
Description: One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study NCT01001195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study NCT01407965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microdialysis catheter
Description: Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
Study NCT03018756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer.
Study NCT03018756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution will be inhaled via nebulizer
Study NCT02293876 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LACRIBELL®
Description: Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
Study NCT02293876 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LIPOSIC®
Description: Carbomer and Sorbitol based gel, used in the treatment of dry eye.
Study NCT02293876 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Glad wrap
Description: A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
Study NCT00968591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT01352390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: A prompt to have their child their health test reminder mailing to color
Study NCT02665754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILIT with extract of causal allergen
Description: 0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
Study NCT02665754 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ILIT with normal saline
Description: 0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
Study NCT02665754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication for allergic rhinitis
Description: Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
Study NCT02665754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication for allergic rhinitis
Description: Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
Study NCT01377857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $1, $5, or $10 incentive
Study NCT01377857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Timing
Description: Timing of the questionnaire--either before or after testing is offered.
Study NCT01377857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Test Offering
Description: HIV Test will be offered as opt-in, opt-out, or active choice.
Study NCT00350935 — intervention group
Intervention type: PROCEDURE
Intervention: fMRI
Description: One 30 minute session
Study NCT03585595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering strategy
Description: The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
Study NCT03585595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure lowering strategy
Description: The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
Study NCT03046732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementing Explore Transplant Education
Description: The Explore Transplant Ontario (ETO) education program